Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28466833 | 0.85 | CYP3A4 (0.37) | KDM4EALDH1A1KMT2ATSHRCYP3A4 | |
| SCHEMBL30786011 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2ATSHRCYP3A4 | |
| SCHEMBL23095680 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL28466832 | 0.78 | KDM4E (0.36) | KDM4EALDH1A1KMT2A | |
| SCHEMBL9063789 | 0.78 | FAAH (0.51) | KMT2A | |
| SCHEMBL22729315 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1KMT2ATSHRCYP3A4 | |
| SCHEMBL29169706 | 0.77 | ANPEP (0.45) | KDM4EALDH1A1KMT2ATSHRPOLB | |
| SCHEMBL10044369 | 0.77 | TSHR (0.56) | KDM4EALDH1A1KMT2ATSHRCYP2D6 | |
| SCHEMBL20176413 | 0.77 | TSHR (0.47) | KDM4EALDH1A1KMT2ANAMPTTSHR | |
| SCHEMBL11798060 | 0.77 | CYP3A4 (0.56) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975132-B2 | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | PLAS-FREE LTD (IL) | 2024-05-07 | — | — | US | disclosed |
| EP-3746151-B1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS FREE LTD (IL) | 2024-04-24 | — | — | EP | disclosed |
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD (IL) | 2021-01-07 | — | — | US | disclosed |
| EP-3746151-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLAS-FREE LTD. (IL) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210001023-A1 | EXTRACORPOREAL DEVICE AND MATRIX FOR REMOVING FIBRINOLYTIC PROTEINS FROM BIOLOGICAL FLUIDS, METHODS AND USES THEREOF | PLG, FGB, PLAU | KDM4E 478/4885ALDH1A1 3862/4885KMT2A 1705/4885 |
| US-11975132-B2 | Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof | PLG, FGB, PLAU | KDM4E 478/4885ALDH1A1 3862/4885KMT2A 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.